Evidence map›Paper›PMID 33413438›Full record

ArticleCell communication and signaling : CCS2021

FAK displacement from focal adhesions: a promising strategy to target processes implicated in cancer progression and metastasis.

Ioanna Antoniades, Maria Kyriakou, Anna Charalambous, Katerina Kalalidou, Andri Christodoulou, Maria Christoforou, Paris A Skourides

Open access · goldAbstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Actin cytoskeletal dynamics in hepatic myofibroblasts and fibrosis.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. The gasdermin family: emerging therapeutic targets in diseases.Signal transduction and targeted therapy · 2024
    Review
  10. Article
  11. Article
  12. FAK in Cancer: From Mechanisms to Therapeutic Strategies.International journal of molecular sciences · 2022
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ioanna Antoniades *Department of Biological Sciences, University of Cyprus, P.O. Box 20537, 2109, Nicosia, Cyprus.
Maria Kyriakou *Department of Biological Sciences, University of Cyprus, P.O. Box 20537, 2109, Nicosia, Cyprus.
Anna CharalambousDepartment of Biological Sciences, University of Cyprus, P.O. Box 20537, 2109, Nicosia, Cyprus.
Katerina KalalidouDepartment of Biological Sciences, University of Cyprus, P.O. Box 20537, 2109, Nicosia, Cyprus.
Andri ChristodoulouDepartment of Biological Sciences, University of Cyprus, P.O. Box 20537, 2109, Nicosia, Cyprus.
Maria ChristoforouDepartment of Biological Sciences, University of Cyprus, P.O. Box 20537, 2109, Nicosia, Cyprus.
Paris A SkouridesDepartment of Biological Sciences, University of Cyprus, P.O. Box 20537, 2109, Nicosia, Cyprus. skourip@ucy.ac.cy.ORCID 0000-0003-3502-5729
University of Cyprus · CY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFocal adhesion kinase (FAK) is a non-receptor tyrosine kinase that is overexpressed or activated in several advanced-stage solid cancers. It is known to play both kinase-dependent and -independent roles in promoting tumor progression and metastasis. Numerous inhibitors, targeting either the enzymatic or scaffolding activities of FAK have been generated, with varying degree of success. Here, we describe a novel approach to site-specifically target both kinase-dependent and -independent FAK functions at focal adhesions (FAs), the primary sites at which the kinase exerts its activity.

methodsWe took advantage of the well-characterized interactions between the paxillin LD motifs and the FAK FAT domain and generated a polypeptide (LD2-LD3-LD4) expected to compete with interactions with paxillin. Co-immunoprecipitation experiments were performed to examine the interaction between the LD2-LD3-LD4 polypeptide and FAK. The effects of LD2-LD3-LD4 in the localization and functions of FAK, as well as FA composition, were evaluated using quantitative immunofluorescence, cell fractionation, FA isolation and Western Blot analysis. Live cell imaging, as well as 2-D migration and cell invasion assays were used to examine the effects on FA turnover and tumor cell migration and invasion.

resultsExpression of the LD2-LD3-LD4 polypeptide prevents FAK localization at FAs, in a controlled and dose-dependent manner, by competing with endogenous paxillin for FAK binding. Importantly, the LD2-LD3-LD4 peptide did not otherwise affect FA composition or integrin activation. LD2-LD3-LD4 inhibited FAK-dependent downstream integrin signaling and, unlike existing inhibitors, also blocked FAK's scaffolding functions. We further show that LD2-LD3-LD4 expression markedly reduces FA turnover and inhibits tumor cell migration and invasion. Finally, we show that dimers of a single motif, linked through a flexible linker of the proper size, are sufficient for the displacement of FAK from FAs and for inhibition of tumor cell migration. This work raises the possibility of using a synthetic peptide as an antimetastatic agent, given that effective displacement of FAK from FAs only requires dimers of a single LD motif linked by a short flexible linker.

conclusionIn conclusion, these results suggest that FAK displacement from FAs is a promising new strategy to target critical processes implicated in cancer progression and metastasis. Video abstract.

Indexed as

Cell LineCell MovementDisease ProgressionFocal Adhesion Protein-Tyrosine KinasesFocal AdhesionsHumansNeoplasmsPaxillinProtein DomainsFocal Adhesion Protein-Tyrosine KinasesPaxillinPXN protein, humanCancerCell invasionCell migrationFocal adhesion kinase (FAK)Focal adhesionsPaxillin

Identifiers

PMID33413438
PMCPMC7791867
OpenAlexW3118305656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.